Balyasny Asset Management
BBIO icon

Balyasny Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Balyasny Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.6M Buy
1,230,052
+879,956
+251% +$61.6M 0.11% 208
2026
Q1 		$26M Buy
350,096
+115,707
+49% +$8.39M 0.03% 586
2025
Q4 		$17.9M Sell
234,389
-780,288
-77% -$51.2M 0.02% 769
2025
Q3 		$52.7M Sell
1,014,677
-626,943
-38% -$30.6M 0.07% 349
2025
Q2 		$70.9M Buy
1,641,620
+841,545
+105% +$30.6M 0.11% 228
2025
Q1 		$27.7M Buy
+800,075
New +$27M 0.05% 483
2024
Q4 		– Sell
-518,806
Closed -$13.2M – 2736
2024
Q3 		$13.2M Buy
518,806
+311,526
+150% +$8.18M 0.02% 815
2024
Q2 		$5.25M Buy
+207,280
New +$5.67M 0.01% 1147
2023
Q2 		– Sell
-220,090
Closed -$3.65M – 2276
2023
Q1 		$3.65M Buy
+220,090
New +$2.57M 0.01% 1200
2022
Q2 		– Sell
-36,786
Closed -$373K – 2744
2022
Q1 		$373K Buy
+36,786
New +$378K ﹤0.01% 1876

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Balyasny Asset Management's BBIO Position: Q2 2026 in Review

Balyasny Asset Management increased its BridgeBio Pharma (BBIO) stake by 251% in Q2 2026, buying an estimated $61.6M and bringing the position to 1,230,052 shares worth $91.6M. The position accounts for 0.11% of the portfolio, ranked #208.

Balyasny Asset Management first reported a position in BBIO in Q1 2022 and has held it in 10 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Balyasny Asset Management held 1,230,052 shares of BridgeBio Pharma worth $91.6M as of Q2 2026.
  • Balyasny Asset Management bought 879,956 BridgeBio Pharma shares in Q2 2026, an estimated $61.6M.
  • BridgeBio Pharma made up 0.11% of Balyasny Asset Management's portfolio in Q2 2026, its #208 holding.
  • Balyasny Asset Management first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 10 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.